Colistin Nephrotoxicity in Adults: Single Centre Large Series from India

Limited Indian data are available on the rate of colistin nephrotoxicity and other risk factors contributing to the development of this important side effect. This study aims to generate data on colistin nephrotoxicity from a large cohort of Indian patients. Retrospective cohort study. Case record analysis of patients who received colistin, in an oncology center in India, between January 2011 and December 2015. Nephrotoxicity was assessed using risk, injury, failure, loss, and end-stage (RIFLE) criteria. P < 0.05 was considered as statistically significant. Out of the 229 patients, 13.1% (30/229) developed abnormal RIFLE. Abnormal RIFLE group ( = 30), in comparison to the normal renal function group ( = 199), had higher number of patients in intensive care unit (ICU) (96% vs. 79%, = 0.02), higher Acute Physiology and Chronic Health Evaluation (APACHE II) score (23 vs. 19 = 0.0001), Charlson score (5.9 vs. 4.3, = 0.001), mechanical ventilation (90% vs. 67%, = 0.016), 28 days mortality (63% vs. 25%, = 0.0001), and abnormal baseline creatinine (36% vs. 8%, = 0.001). Coadministration of vancomycin had higher rates of nephrotoxicity ( = 0.039). There was no significant difference in nephrotoxicity between 6 and 9 MU/day dosing pattern (8.8% vs. 13.8%, = 0.058). Nephrotoxicity rate in our retrospective single center large series of patients receiving colistin was 13.1%. Patients with abnormal baseline creatinine, ICU stay, and higher disease severity are at higher risk of nephrotoxicity while on colistin. A daily dose of 9 million does not significantly increase nephrotoxicity compared to the 6 million. Concomitant administration of vancomycin with colistin increases the risk of nephrotoxicity.